Enoxaparin versus Unfractionated Heparin in Elective Percutaneous Coronary Intervention | Zendy

Gilles Montalescot | Zendy; Harvey D. White | Zendy; Richard L. Gallo | Zendy; Marc Cohen | Zendy; Philippe Gabríel Steg | Zendy; Philip E. Aylward | Zendy; Christoph Bode | Zendy; Massimo Chiariello | Zendy; Spencer B. King | Zendy; Robert A. Harrington | Zendy; Walter Desmet | Zendy; Carlos Macaya | Zendy; Steven R. Steinhubl | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Enoxaparin versus Unfractionated Heparin in Elective Percutaneous Coronary Intervention

Author(s) -

Gilles Montalescot,

Harvey D. White,

Richard L. Gallo,

Marc Cohen,

Philippe Gabríel Steg,

Philip E. Aylward,

Christoph Bode,

Massimo Chiariello,

Spencer B. King,

Robert A. Harrington,

Walter Desmet,

Carlos Macaya,

Steven R. Steinhubl

Publication year - 2006

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa052711

Subject(s) - medicine , heparin , percutaneous coronary intervention , conventional pci , enoxaparin sodium , activated clotting time , anticoagulant , anesthesia , surgery , bivalirudin , low molecular weight heparin , myocardial infarction

Despite its limitations, unfractionated heparin has been the standard anticoagulant used during percutaneous coronary intervention (PCI). Several small studies have suggested that intravenous enoxaparin may be a safe and effective alternative. Our primary aim was to assess the safety of enoxaparin as compared with that of unfractionated heparin in elective PCI.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research